12 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 9 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 4 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1068.58, along with a high estimate of $1184.00 and a low estimate of $850.00. Observing a 3.16% increase, the current average has risen from the previous average price target of $1035.86.
Analyzing Analyst Ratings: A Detailed Breakdown
An in...
Login or create a forever free account to read this news
Sign up/Log in